DUBLIN, Feb. 3, 2017 /PRNewswire/ -- Allergan plc (NYSE:
AGN) today announced that its Board of Directors is proceeding with
its previously announced cash dividend of $0.70 per ordinary share for the first quarter of
2017. The dividend will be paid on March
28th, 2017 to shareholders of record at the close
of business on February
28th, 2017.
"Allergan's first dividend highlights our continued confidence
in our long-term business strategy, profitability and strong cash
flows, while reinforcing our commitment to maximizing shareholder
returns. We expect to increase our dividend on an annual basis over
time. We also retain firepower to continue strengthening our growth
through investment in accretive transactions and stepping stone
R&D deals," said Brent Saunders,
Chairman, CEO and President of Allergan.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceuticals, devices
and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the
Company's R&D model, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. This approach has led to Allergan building one
of the broadest development pipelines in the pharmaceutical
industry with 70+ mid-to-late stage pipeline programs in
development.
Our Company's success is powered by our more than 16,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Payment of the ordinary
share divident is subject to applicable law. Actual results
may differ materially from Allergan's current expectations
depending upon a number of factors affecting Allergan's business.
These factors include, among others, the difficulty of predicting
the timing or outcome of FDA approvals or actions, if any; the
impact of competitive products and pricing; market acceptance of
and continued demand for Allergan's products; difficulties or
delays in manufacturing; and other risks and uncertainties detailed
in Allergan's periodic public filings with the Securities and
Exchange Commission, including but not limited to Allergan's Annual
Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form
10-Q for the quarter ended September 30,
2016. Except as expressly required by law, Allergan
disclaims any intent or obligation to update these forward-looking
statements.
CONTACTS:
|
Allergan:
|
|
Investors:
|
|
Lisa
DeFrancesco
|
|
(862)
261-7152
|
|
|
|
Media:
|
|
Mark
Marmur
|
|
(862)
261-7558
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-declares-first-quarterly-cash-dividend-of-070-per-ordinary-share-300401787.html
SOURCE Allergan plc